Registered Rwanda · Rwanda FDA

CIDINE

Cinitapride, 1mg

Rwanda FDA-HMP-MA-1030 Tablets 1mg alimentary tract and metabolism INN generic

What it does

Cinitapride is a medication that helps with digestive issues by improving the movement in the stomach and intestines.

Commonly used for: stomach discomfort, nausea, heartburn, gastroesophageal reflux disease (GERD)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
Rwanda FDA-HMP-MA-1030
Registration date
28/02/2024
Expiry date
27/02/2029
Status
Registered
Active ingredient
Cinitapride, 1mg
Dosage form
Tablets
Strength
1mg
Pack size
5x10 Tablets
Therapeutic class
-
ATC class (WHO)
A03FA - Propulsives
Drug group
ALIMENTARY TRACT AND METABOLISM
RxNorm RxCUI
21125
Manufacturer / MAH
Almirall
Applicant / LTR
ALMIRALL, S.A.
Country of origin
SPAIN
Manufacturer location
Ctra. de Martorell, 41-61, 08740 Sant Andreu de la Barca, Barcelona, Spain

Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:19 · updated 2026-09-17 02:30:43

Disclaimer: This information is sourced from Rwanda Food and Drugs Authority (Rwanda). Always consult a qualified healthcare professional before using any medication.

About this medicine

Cinitapride is a medication that helps with digestive issues by improving the movement in the stomach and intestines.

What it treats

  • stomach discomfort
  • nausea
  • heartburn
  • gastroesophageal reflux disease (GERD)

How it works

It works by increasing the movement in the digestive tract, helping food to pass through more easily.

Who it's for

This medicine is for adults experiencing digestive problems.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: cinitapride

BNF-referenced

Cinitapride is a substituted benzamide used primarily for its gastroprokinetic properties. It acts on the gastrointestinal tract to enhance motility and reduce symptoms associated with gastrointestinal disorders. It is particularly beneficial in treating conditions like functional dyspepsia and gastroesophageal reflux disease (GERD).

Indications

  • Functional dyspepsia
  • Gastroesophageal reflux disease (GERD)
  • Nausea
  • Bloating

Dosage

Children: Refer to BNF for Children for specific dosing guidance.

Adults: Refer to BNF for specific dosing guidance.

Mechanism of action

Cinitapride exhibits activity as both a 5-HT receptor antagonist and agonist. This dual action helps to modulate neurotransmitter activity in the gastrointestinal tract, enhancing peristalsis and improving gastric emptying.

Pharmacodynamics

Cinitapride's pharmacodynamic profile is characterized by its ability to stimulate 5-HT4 receptors, which promote gastrointestinal motility, while also blocking 5-HT3 receptors, which can inhibit excessive gastrointestinal contractions. This balance helps manage symptoms such as nausea, bloating, and discomfort.

Pharmacokinetics

Cinitapride is well absorbed after oral administration. It undergoes extensive metabolism in the liver and has a moderate half-life, necessitating multiple doses throughout the day to maintain effective therapeutic levels. The drug is primarily excreted via urine, with metabolites being the main form of excretion.

Contra-indications

  • Hypersensitivity to cinitapride or any of its components
  • Pheochromocytoma
  • Severe renal impairment
  • Severe hepatic impairment
  • Gastrointestinal obstruction

Adverse effects

  • Drowsiness
  • Dizziness
  • Headache
  • Nausea
  • Diarrhea
  • Dry mouth
  • Abdominal cramps
  • Extrapyramidal symptoms
  • Allergic reactions

Interactions

  • Caution with other central nervous system depressants
  • May enhance the effects of anticholinergic drugs
  • Potential interaction with drugs that affect cytochrome P450 enzymes

Precautions

  • Use with caution in patients with a history of seizures
  • Monitor for signs of tardive dyskinesia in long-term use
  • Assess renal and hepatic function before initiating therapy

Pregnancy

Limited data on the use of cinitapride in pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Cinitapride is excreted in breast milk. Caution should be exercised when administered to a nursing mother.

Storage

Store below 25 degrees Celsius. Keep in a tightly closed container, protected from light.

Formulations

  • Tablets
  • Oral solution
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: cinitapride

PubChem CID 68867

Molecular formula: C21H30N4O4

Mechanism of action

Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.